Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with
unmet medical needs for global markets. In addition to this announcement, Dimerix is currently developing its
proprietary product DMX-200 for both Diabetic Kidney Disease and Focal Segmental Glomerulosclerosis (FSGS). DMX200 was identified using Dimerix’ proprietary assay, Receptor Heteromer Investigation Tech...
Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with
unmet medical needs for global markets. In addition to this announcement, Dimerix is currently developing its
proprietary product DMX-200 for both Diabetic Kidney Disease and Focal Segmental Glomerulosclerosis (FSGS). DMX200 was identified using Dimerix’ proprietary assay, Receptor Heteromer Investigation Technology.
Upgrade this company profile// Update & customize all content. Ask PharmaCompass, click HERE.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
